耳鼻咽喉科領域におけるCefmetazoleの体内動態および臨床使用だ

抄録

Cefmetazole (CMZ), a new cephamycin preparation, has been investigated to give following results.
1) Pharmacokinetics: Serum and tonsil concentration of CMZ were determined by micropore method in humans.The mean concentrations in 5 cases about 30 minutes after administration of 0.5-1.0g intravenously were 55.4μg/ml in serum, 2 1.7μg/g in tonsil.
2) Clinical studies: Seventy-one patients with ear, nose and throat infections were treated with CMZ receiving 1 to 6g per day intravenously (one shot and drip infusion). Thirty-eight of 70 patients were cured excellent, 19 were good, 8 were fair and 6 were failure and effective rate was 80.3%.Adverse reaction was observed in 4 cases. Three cases showed exanthema and 1 case showed fever elevation.